China Meheco Group (SHA:600056) obtained drug registration certificates for clindamycin phosphate and norepinephrine bitartrate injections from China's drug administrator.
Clindamycin phosphate is mainly suitable for treating serious infections caused by sensitive anaerobic bacteria, while norepinephrine bitartrate is used for controlling blood pressure, according to Friday filings with the Shanghai bourse.
Shares of the pharmaceutical company were down 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments